| Bioactivity | Zasocitinib (NDI-034858) is a TYK2 inhibitor, target TYK2 JH2 domain with binding constant Kd of <200 pM[1]. | ||||||||||||
| Target | Tyk2 JH2 domain | ||||||||||||
| Invitro | Zasocitinib (10 μM) exhibits inhibitory effect on Tyk2 and JAK by targeting Tyk2 JH1 and JAK JH1 domain with inhibition rates <50%, respectively[1].Zasocitinib inhibits phosphorylation induction of heterodimer complex Tyk2 /JAK2-mediated IL-12 (1.7 ng/mL) effect, with IC50 value of <0.1 μM in human peripheral blood mononuclear cell[1]. | ||||||||||||
| Name | Zasocitinib | ||||||||||||
| CAS | 2272904-53-5 | ||||||||||||
| Formula | C23H24N8O3 | ||||||||||||
| Molar Mass | 460.49 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Masse, Craig E, et al. Pyrazolopyrimidines as TYK2 inhibitors and their preparation: World Intellectual Property Organization, WO2019023468. 2019-01-31. |